Retatrutide’s Phase 2 data reflects tightly managed populations: BMI thresholds, exclusion criteria, frequent follow-up. In one cohort, adherence exceeded 85%, with structured dose escalation protocols mitigating early discontinuation. This is not how patients behave outside trial conditions.
The variance begins early. Dose titration—necessary to manage tolerability—introduces temporal inefficiency. In practice, escalation may stall. Side effects persist. Patients drift. The mean outcome begins to fracture.
Subgroup analysis complicates interpretation further. Younger patients with fewer comorbidities demonstrate stronger responses. Those with longstanding metabolic disease show attenuation. The average masks divergence.
Real-world evidence from semaglutide suggests drop-off rates approaching 40% within one year. There is little reason to assume retatrutide will behave differently, despite improved efficacy. Better drugs do not necessarily produce better adherence.
There is also a structural bias in endpoints. Weight loss is measurable. Functional improvement is less so. Trials capture kilograms. They struggle to capture sustained behavioral adaptation, which remains the determinant of long-term outcomes.
Regulators evaluate safety and efficacy. They do not evaluate persistence. Yet persistence is the variable that determines cost-effectiveness.
The gap between trial and practice is not a flaw. It is a feature of the system. But it does mean that clinical data, however precise, is only a partial description of reality.
Real-world evidence from semaglutide suggests drop-off rates approaching 40% within one year. There is little reason to assume retatrutide will behave differently, despite improved efficacy. Better drugs do not necessarily produce better adherence.
There is also a structural bias in endpoints. Weight loss is measurable. Functional improvement is less so. Trials capture kilograms. They struggle to capture sustained behavioral adaptation, which remains the determinant of long-term outcomes.
Regulators evaluate safety and efficacy. They do not evaluate persistence. Yet persistence is the variable that determines cost-effectiveness.
The gap between trial and practice is not a flaw. It is a feature of the system. But it does mean that clinical data, however precise, is only a partial description of reality.
